Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
For prescribers, pharmacists, and nurses
GLP1Zoom maintains an editorial dataset on every FDA-approved and compounded GLP-1 workflow. This page surfaces the resources we built specifically for healthcare professionals — dosing references, interaction lookups, and evidence reviews. No sales, no provider rankings.
Editorial datasets cross-checked against FDA labels. Last full audit: 2026-05.
Quick-reference titration schedules and max doses for all 18 GLP-1 medications, pulled from FDA labels.
Open →HCP-optimized version of the interaction lookup. Adversarially verified clinical management notes and FDA-label citations.
Open →263 GLP-1 × comorbidity medication pages with mechanism, severity, monitoring guidance.
Open →Live FDA shortage status for semaglutide, tirzepatide, liraglutide products with last-checked timestamps.
Open →Evidence reviews for GLP-1 use in T2D, obesity, NAFLD, PCOS, sleep apnea, cardiovascular indications.
Open →What changed after FDA declared shortage end (Oct 2024): 503A scope, market dynamics, prescribing considerations.
Open →These tools are public and free. Many HCPs link them in after-visit summaries or hand them to patients with denial letters.
Free patient-facing tool that auto-drafts payer-specific medical-necessity appeal letters. Have patients open it directly or use it during the visit.
12-month all-in cost comparison across brand-name, compounded, and insurance-covered paths for any GLP-1.
Quickly verify FDA-indication thresholds (BMI ≥ 30 or ≥ 27 with comorbidity) for chronic weight management.
60-second patient self-screen for prescribing readiness. Useful as a pre-visit triage when EMR doesn't capture full obesity history.
GLP1Zoom is not currently an ACCME provider. Pages here do not award CME hours. We're tracking interest in a future CME partnership with an accredited education organization — if you'd find that valuable, let us know via the contact form with category "Medical advisory".
No-sales pledge. This page is editorial. We do not place affiliate links, partner recommendations, or commercial messaging on /hcp pages. The patient-facing site is affiliate-supported (affiliate disclosure); the HCP section is not.
Limitations. GLP1Zoom is an editorial resource, not a substitute for clinical judgment. Doses, contraindications, and management decisions should always reference the current FDA label and your local formulary.
Suggest a resource we're missing.
Email [email protected] or use the contact form with category "Medical advisory".
Contact editorial